Defective pro-SFTPC does not translocate from ER membrane to multivesicle body

Stable Identifier
R-HSA-5688377
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Surfactant proteins (SFTPs) are trafficked from the ER membrane to lamellar bodies (LBs) via the multi-vesicle body (MVB). The pro-SFTPs B and C are cleaved here to produce functional SFTPs. Defects in the SFTPC gene result in protein misfolding, misrouting and/or misprocessing resulting in accumulation of partially-processed, inactive pro-SFTPC in alveoli causing cell toxicity. Defects in SFTPC can cause pulmonary surfactant metabolism dysfunction 2 (SMDP2; MIM:610913), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Cellular responses to the misfolded pro-SFTPC products include ER stress, the activation of reactive oxygen species and autophagy. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450). Mutations causing RDS that arrest the pro-protein in the ER include P30L and P115L (Thurm et al. 2013).

Literature References
PubMed ID Title Journal Year
23701443 SFTPC mutations cause SP-C degradation and aggregate formation without increasing ER stress

Thurm, T, Kaltenborn, E, Kern, S, Griese, M, Zarbock, R

Eur. J. Clin. Invest. 2013
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
interstitial lung disease 3082 ILD
newborn respiratory distress syndrome 12716 Neonatal respiratory Distress syndrome, hyaline membrane disease, HMD - Hyaline membrane disease, pulmonary hypoperfusion syndrome of newborn, respiratory distress syndrome of newborn, pulmonary hyaline membrane disease
Authored
Reviewed
Created